Health Care • Biotechnology: Pharmaceutical Preparations
$1.00 ▲ +0.02
(+1.53%)
MKT CAP: $18.9M • VOL: 62.8K
52W L $1 52W H $2
ROARABLE / RQD
D- • 35/100
PIOTROSKI
3 / 9
COCP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$9.0M | -$17.9M | -$18.6M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$8.8M | -$17.5M | -$18.0M |
| EBITDA (Normalized) | -$9.0M | -$17.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.2M | -$16.5M | -$14.7M |
| Capital Expenditures (CapEx) | $12.0K | $8.0K | — |
| Free Cash Flow (FCF) | -$8.2M | -$16.5M | -$14.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $7.0M | $9.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $6.3M | $9.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR COCP.